Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.
Also called NCT04798430
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,000 participants
- Registry
-
NCT04798430
-
- Other papers using this trial's data
- Response to PCSK9 Inhibition Based on LDL Receptor Function in Familial Hypercholesterolemia: A Nonrandomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, India, Israel, Norway, South Africa, Türkiye
- Registry status
- Unknown status
Technical summary
Registry record NCT04798430. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-03 (actual); primary completion 2025-07-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
- Acronym
- LIBerate-OLE
- Condition
- Cardiovascular Disease With Mention of Arteriosclerosis
- Condition
- Elevated Cholesterol
- Condition
- Familial Hypercholesterolemia
- Intervention (Drug)
- lerodalcibep
- Lead sponsor
- LIB Therapeutics LLC
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct04798430- Content hash
3104b60797b0a0ffad04bf1626ee1f4e422e45ab159e63c26c5c52654dc538dc